Incidence and pattern of anticoagulation in patients with atrialfibrillation and atrial flutter at tertiary hospital in Oman
Main Article Content
Keywords
anticoagulation, atrial fibrillation, atrial flutter
Abstract
Background: Atrial fibrillation (AF) and atrial flutter (AFL) are the two most common cardiac arrhythmias encountered in clinical practice. Anticoagulants are the cornerstone in cerebrovascular accident prevention in these patients. Despite their role in reducing stroke risk, emergency room visits, and overall treatment costs, studies have shown that oral anticoagulants (OAC) are underutilized, even in high-risk patients. Objective: The aim of this study is to explore the appropriateness and pattern of anticoagulant prescriptions in patients with AF and/or AFL in a tertiary hospital as recommended by the international guidelines. Method: This retrospective observational study was conducted by reviewing the electronic medical records of 389 adult patients with either AF or AFL in Sultan Qaboos University Hospital (SQUH) between July 2018 and July 2020. The appropriateness of oral anticoagulation was assessed according to international guidelines, namely, 2020 Canadian Cardiology Society (CCS), 2020 European Society of Cardiology (ESC), and 2019 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS). Analysis was performed using univariate statistics (Chi-square and percentages) to report categorical data. Results: Oral anticoagulants were prescribed appropriately in 91% of the patients according to CCS guidelines, and 92% and 96% according to ESC and (AHA/ACC/HRS) class Ia and IIa recommendations, respectively. Among non-anticoagulated patients (28 patients, 9%) had proper justification. On the other hand, 38 patients (9.8%) out of the whole cohort (389) had a CHADS-65 score of zero but received OAC mostly due to cardioversion, rheumatic heart disease, or mechanical heart valve prosthesis. Novel oral anticoagulants (NOACs) were the most commonly used OAC 251/336 (75%), with rivaroxaban being the main drug used 234/250 (92%) of all NOAC prescriptions. 75% of patients with eGFR<50 ml/min received the proper dose of rivaroxaban. Bleeding was the most frequently reported side effect of OAC in 52 (13.4%) of the entire cohort. Conclusion: Nearly 91% of patients with AF/AFL followed at SQUH were prescribed an appropriate anticoagulant as per international guidelines. The decisions to anticoagulate a patient with AF/AFL and the type of anticoagulant used were appropriate.
References
https://doi.org/10.11909/j.issn.1671-5411.2017.03.011
2. Leonard. Uptodate.2020. [Online]. Available: https://www.uptodate.com/contents/epidemiology-of-and-risk-factors-foratrialfibrillation
[Accessed 12 December 2020].
3. Riles SM. Classification and mechanisms of atrial flutter. ESC CardioMed. 2018. [Online]. Available: https://oxfordmedicine.
com/view/10.1093/med/9780198784906.001.0001/med9780198784906 chapter-517. [Accessed 5 December 2020].
4. Salam A. Atrial fibrillation in Middle Eastern Arabs and South Asians: Summary of published articles in the Arabian Gulf. Heart
Failure Rev.2019;20(4):158. https://doi.org/10.4103/heartviews.heartviews_116_19
5. Jakub G, Magdalena D, Marco P, Yan GL, Nidal A, Wafa R, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE). J Am Heart
Assoc. 2020;9(5):1286. https://doi.org/10.1161/circoutcomes.110.959700
6. Jason GA, Martin A, Clare A, Alan B, John AC, Christopher C, et al. Canadian Cardiovascular Society/Canadian Heart Rhythm
Society Comprehensive, 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines
for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847-1948. https://doi.org/10.1016/j.cjca.2020.09.001
7. Paul D, Werner J, David N, Miney P, Kathryn W, Gregory MA, et al. The impairment of health-related quality of life in patients with
intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36(4):1303-9.
https://doi.org/10.1016/s0735-1097(00)00886-x
8. Hirotsugu A, Hiroshi I, Ken O, Takeshi Y, Naoko K, Hideki O. Present status of anticoagulation treatment in Japanese patients
with atrial fibrillation: a report from the J‐RHYTHM Registry. Circ Res. 2011;75(6):1328-33. https://doi.org/10.1253/circj.cj-10-
1119
9. Brett D, Jose AJ, Alberto JL, Hadar LT. Treatments to prevent primary venous ulceration after deep venous thrombosis. J Vasc
Surg Venous Lymphat Disord. 2019;7(2):260-71. https://doi.org/10.1016/j.jvsv.2018.12.009
10. Akash R, Kenneth YK, Shawn DS, Dipayon R, Youning Z, Jonathan N, et al. Anticoagulation Patterns in Patients with Atrial
Fibrillation Following Percutaneous Coronary Intervention in an Academic Center. J Innov Card Rhythm Manag. 2019;10(8):3785-
9. https://doi.org/10.19102/icrm.2019.100802
11. Andrea LS, Michael OF, David B, Louisa RJ, Andrew W, Melanie H, et al. Evidence‐Practice Gaps in Postdischarge Initiation
with Oral Anticoagulants in Patients with Atrial Fibrillation. J Am Heart Assoc. 2019;8(24):e014287. https://doi.org/10.1161/
jaha.119.014287
12. Michael WC, Sunghee K, Jonathan PP, Jack EA, Gerg CF, Elaine MH, et al. Risks and Benefits of Anticoagulation in Atrial
Fibrillation. Circulation. 2013;6:461-9
13. Gregory YH, Cécile L, Gheorghe AD, Massimo S, Zbigniew K, Lars HR, et al. Real‐world antithrombotic treatment in atrial
fibrillation: the EURObservational Research Programme Atrial Fibrillation General Pilot survey. Am J Med. 2014;127(6):519-29.
14. Robby N, Alessandro C, Gregory YH, Bertil SO, Martin H, Fred HN, et al. Antithrombotic treatment in real‐life atrial fibrillation
patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27(5):3018-26.
15. Wesley TO, J’Neka SC, Pratik BS, Richard FM, Lin YC, Lindsay GB, et al. Provider Specialty, Anticoagulation Prescription Patterns,
and Stroke Risk in Atrial Fibrillation. J Am Heart Assoc. 2018;72 (16):1913-22.
16. Ajoe JK, Naga VP, Akshay G, Mahanazuddin S, Shorabuddin S, Hakan P, et al. (2019). Prescription Patterns and Outcomes of
Patients with Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis. J. Cardiovasc.
Pharmacol. Ther. 2019;24(5):428-34. https://doi.org/10.1177/1074248419841634
17. Menno VH, Kenneth JR, Miney P, Christine T, Hans CD, Sergio JD, et al. Antithrombotic Treatment Patterns in Patients with
Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. Am. J. Med. 2015;128(12):1306-13. https://
doi.org/10.1016/j.amjmed.2015.07.013
18. Andrew CH, Narendra S, Jafna LC. John M, Paul D, Carl FM, et al. Oral Anticoagulation for Stroke Prevention in Canadian
Practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry. Can J Cardiol. 2016;32(2):204-
10. https://doi.org/10.1016/j.cjca.2015.04.028
19. Xiaomeng Y, Zixiao L, Xingquan Z, Chunjuan W, Liping L, Chaunxue W, et al. Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation in China. Stroke. 2015;47(2):464-70. https://doi.org/10.1161/
strokeaha.115.011833
20. Chunjuan W, Zhonghua Y, Chunxue W, Yilong W, Xingquan Z, Liping L, et al. Significant Underuse of Warfarin in Patients with
Nonvalvular Atrial Fibrillation: Results from the China National Stroke Registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157-63.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.10.006
21. Noritomo N, Ken O, Takahiko K, Joko M, Katsuko T, Reiko T, et al. Trends in Prevalence of Non-Valvular Atrial Fibrillation and
Anticoagulation Therapy in a Japanese Region―Analysis Using the National Health Insurance Database. Circ J. 2020;84(5):706-
13. https://doi.org/10.1253/circj.cj-18-0989
22. Hammoudeh AJ, Khader Y, Kadri N, Al-Mousa E, Badaineh Y, Habahbeh L, et al. Adherence to the 2019 AHA/ACC/HRS Focused
Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial
Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. Int. J. Vasc. Med. 2021;4(2):1-9. https://doi.org/10.1155/2021/5515089
23. Alan SG, Elaine MH, Yuchiao C, Kathleen AP, Lori EH, Angela MC, et al. Anticoagulation therapy for stroke prevention in
atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290(20):2685-92. https://doi.
org/10.1001/jama.290.20.2685
24. Medi C, Hankey GJ, Freedman SB. Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation. J Am. Heart Assoc.
2010;41:2705-13. https://doi.org/10.1161/strokeaha.110.589218
25. Daniel ES, Yuchiao C, Margaret CF, Leila HB, Niela KP, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
Ann Intern Med. 2009;151(5):297-305. https://doi.org/10.7326/0003-4819-152-4-201002160-00017
26. Maneesha M, Julia DB, Alan CF, Roger MM. Impact of relative contraindications on the use, benefits, and risks of anticoagulant
prophylaxis in atrial fibrillation: analysis of a claims database. Open J. Intern. Med. 2011;1(1):60-7.
27. Gunnar HH, Vincent B, Stephan HS. Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. Dtsch Arztebl Int.
2018;115(17):287-94. https://doi.org/10.3238/arztebl.2018.0287
28. Michael DE, Samual LB, Kenneth EJ, Nathan HC, Cindy LC, et al. Warfarin in the prevention of stroke associated with
nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-12. https://doi.org/10.1056/nejm199211123272002
29. Estes MN, Halperin JL, Calkins H, Ezkowitz MD, Gitman P, Go AS, et al. ACC/AHA/Physician Consortium 2008 Clinical Performance
Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter. J Am Coll Cardiol. 2008;51(8):865-84. https://doi.
org/10.1161/circulationaha.107.187192
30. Peter RK, James AR, Robert M, Gerald VN, Douglas LP, Craig MP, et al. AFFECTS Scientific Advisory Committee and Investigators.
Warfarin and aspirin use in atrial fibrillation among practicing cardiologists (from the AFFECTS Registry). Am J Cardiol.
2010;105(8):1130-4. https://doi.org/10.1016/j.amjcard.2009.11.047
31. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ. Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the
national ambulatory medical care survey database. J Am Coll Cardiol. 2007;49(14):1561-5. https://doi.org/10.1016/j.
jacc.2006.11.045
32. Turakhia MP, Hoang DD, Xu X, Frayne S, Schmitt S, Yang F, et al. Differences and trends in stroke prevention anticoagulation in
primary care vs cardiology specialty management of new atrial fibrillation: the Retrospective Evaluation and Assessment of
Therapies in AF (TREAT-AF) study. Am Heart J. 2013;165 (8):93-101. https://doi.org/10.1016/j.ahj.2012.10.010
33. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, J-RHYTHM Registry Investigators. Target Intensity of Anticoagulation
with Warfarin in Japanese Patients with Valvular Atrial Fibrillation. Circulation. 2015;79(2):325-330. https://doi.org/10.1253/
circj.cj-14-1057
34. Wilke T, Bauer S, Muller S, Kohlmann T, Bauersachs R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation:
A Systematic Literature Review. Patient Exp J. 2016;10(1):17-37. https://doi.org/10.1007/s40271-016-0185-9
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.